AR072454A1 - Composiciones que comprenden aspirina, metformina y clorhidrato de serotonina y metodos para el tratamiento de enfermedades hiperproliferativas - Google Patents

Composiciones que comprenden aspirina, metformina y clorhidrato de serotonina y metodos para el tratamiento de enfermedades hiperproliferativas

Info

Publication number
AR072454A1
AR072454A1 ARP090101786A ARP090101786A AR072454A1 AR 072454 A1 AR072454 A1 AR 072454A1 AR P090101786 A ARP090101786 A AR P090101786A AR P090101786 A ARP090101786 A AR P090101786A AR 072454 A1 AR072454 A1 AR 072454A1
Authority
AR
Argentina
Prior art keywords
composition
agent
aspirin
serotonin
metformin
Prior art date
Application number
ARP090101786A
Other languages
English (en)
Original Assignee
Chen Chien Hung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41100614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072454(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chen Chien Hung filed Critical Chen Chien Hung
Publication of AR072454A1 publication Critical patent/AR072454A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion que incluye un primer agente seleccionado entre un agente que posee actividad anti-inflamatoria o acetaminofeno, fenacetina, tramadol y semejantes; un segundo agente seleccionado del grupo que consiste de un inhibidor de la fosforilacion oxidativa, un ionoforo y un activador de la proteína quinasa activada por adenosina 5-monofosfato (AMPK); un tercer agente que posee o conserva la actividad de serotonina. Reivindicacion 2: La composicion de la reivindicacion 1, caracterizada porque la enfermedad hiperproliferativa es un tumor benigno. Reivindicacion 3: La composicion de la reivindicacion 1, caracterizada porque la enfermedad hiperproliferativa es una enfermedad cancerosa. Reivindicacion 32: La composicion de las reivindicaciones 29 o 30, caracterizada porque el primer agente es un compuesto anti-inflamatorio no esteroide. Reivindicacion 33: La composicion de las reivindicaciones 29 o 30, caracterizada porque el primer agente es aspirina, diclofenac, ibuprofeno, indometacina, acetaminofeno, nimesulide, y sus sales, prodrogas y solvatos farmacéuticamente aceptables o un inhibidor de COX-2. Reivindicacion 34: La composicion de las reivindicaciones 29 o 30, caracterizada porque el primer agente es aspirina, aspirina-arginina, L-arginina acetilsalicílico, aspirina-DL-lisina o celecoxib. Reivindicacion 36: La composicion de la reivindicacion 35, caracterizada porque el tercer agente es sulfato de serotonina, complejo de sulfato de serotonina y creatinina o clorhidrato de serotonina. Reivindicacion 48: La composicion de la reivindicacion 46, caracterizada porque el activador de AMPK se selecciona del grupo que consiste de metformina, fenformina, buformina, AICAR, tienopiridonas, resveratrol, nootkatona, tiazol, adiponectina, tiazolidindionas, rosiglitazona, pioglitazona y ditioletionas. Reivindicacion 79: El método de la reivindicacion 75, caracterizado porque la enfermedad hiperproliferativa es cáncer de colon.
ARP090101786A 2008-05-16 2009-05-18 Composiciones que comprenden aspirina, metformina y clorhidrato de serotonina y metodos para el tratamiento de enfermedades hiperproliferativas AR072454A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12788308P 2008-05-16 2008-05-16
US21207209P 2009-04-07 2009-04-07

Publications (1)

Publication Number Publication Date
AR072454A1 true AR072454A1 (es) 2010-09-01

Family

ID=41100614

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090101786A AR072454A1 (es) 2008-05-16 2009-05-18 Composiciones que comprenden aspirina, metformina y clorhidrato de serotonina y metodos para el tratamiento de enfermedades hiperproliferativas

Country Status (20)

Country Link
US (1) US8367645B2 (es)
EP (2) EP2123267B1 (es)
JP (2) JP5697853B2 (es)
KR (2) KR20160037245A (es)
CN (2) CN106983759A (es)
AR (1) AR072454A1 (es)
AU (1) AU2009201946B2 (es)
BR (1) BRPI0903359B8 (es)
CA (1) CA2666036C (es)
CL (1) CL2009001215A1 (es)
DK (1) DK2123267T3 (es)
ES (1) ES2608982T3 (es)
IL (1) IL209336B (es)
MX (1) MX2010012549A (es)
MY (1) MY162563A (es)
RU (1) RU2563833C2 (es)
SA (1) SA109300299B1 (es)
TW (1) TWI496572B (es)
WO (1) WO2009140680A1 (es)
ZA (1) ZA201008201B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI440456B (zh) * 2007-01-16 2014-06-11 用於治療代謝性症候群之新穎化合物
AU2010225923B2 (en) * 2009-03-16 2016-10-27 Ipintl, Llc Treating Alzheimer's disease and osteoporosis and reducing aging
FR2958849A1 (fr) * 2010-04-14 2011-10-21 Boiron Medicament homeopathique a activite anti-cancereuse
US20130059916A1 (en) * 2010-05-26 2013-03-07 Stephane Rocchi Biguanide compounds and its use for treating cancer
JP5378469B2 (ja) * 2011-08-11 2013-12-25 学校法人 日本歯科大学 医療用薬剤
CN106421795A (zh) * 2012-10-08 2017-02-22 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
WO2015168022A1 (en) * 2014-04-27 2015-11-05 The Research Foundation For The State University Of New York Enamel products and methods of use
CN109414419A (zh) * 2016-06-15 2019-03-01 德国癌症研究中心 通过同时靶向能量代谢和细胞内pH进行癌症治疗
CN106138021A (zh) * 2016-08-11 2016-11-23 温州医科大学附属第二医院 二甲双胍作为治疗椎间盘退行性病药物中活性成分的应用
ES2684408B1 (es) * 2017-03-31 2019-07-09 Univ Granada Uso de melatonina para el tratamiento de tumores
US11208475B1 (en) * 2018-01-30 2021-12-28 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators
US20230219889A1 (en) 2020-05-19 2023-07-13 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN113599370B (zh) * 2021-08-03 2023-12-08 复旦大学附属肿瘤医院 8-oh-dpat及其衍生物在制备抗肿瘤药物中的应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US5100919A (en) 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
GB9311132D0 (en) 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
DE69520528T2 (de) * 1994-06-14 2001-09-27 Raffinerie Tirlemontoise, S.A. Verwendung einer Zusammensetzung enthaltend Inulin oder Oligofructose als Antikrebsmittel
DE9414065U1 (de) 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5981168A (en) * 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US20040053900A1 (en) 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
EP1178789B1 (en) 1999-03-19 2008-07-16 Abbott GmbH & Co. KG Method of treating eating disorders
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
RU2266734C2 (ru) * 1999-05-13 2005-12-27 Фарма Мар, С.А. Композиции и применение ет743 для лечения злокачественных опухолей
US6495538B2 (en) * 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents
CA2373940A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
DE19949319A1 (de) 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
GB0004003D0 (en) 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6927223B1 (en) * 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
WO2002010169A1 (en) 2000-07-31 2002-02-07 F. Hoffmann-La Roche Ag Piperazine derivatives
AR038762A1 (es) 2000-10-16 2005-01-26 Hoffmann La Roche Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento
WO2002036596A2 (en) 2000-11-03 2002-05-10 Wyeth CYCLOALKYL[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES
WO2002038142A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
EP1337518B1 (en) 2000-11-20 2009-06-17 Biovitrum AB (publ) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
PL361690A1 (en) 2000-11-20 2004-10-04 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
KR100539143B1 (ko) 2000-12-27 2005-12-26 에프. 호프만-라 로슈 아게 인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도
EP1302465A1 (en) 2001-10-11 2003-04-16 BRACCO IMAGING S.p.A. Enhanced substrate imaging by reversible binding to a paramagnetic complex
US6995181B2 (en) * 2002-07-18 2006-02-07 Bristol-Myers Squibb Co. Modulators of the glucocorticoid receptor and method
AU2003272790A1 (en) * 2002-10-08 2004-05-04 Honeywell International Inc. Semiconductor packages, lead-containing solders and anodes and methods of removing alpha-emitters from materials
US20060147947A1 (en) * 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
PT1558220E (pt) * 2003-07-24 2010-03-12 Rasendrakumar Jha Composições orais para tratamento da diabetes
JP2007503396A (ja) * 2003-08-22 2007-02-22 ファルマシア コーポレイション 新形成の治療のためのシクロオキシゲナーゼ−２選択的阻害剤及びセロトニン−調節剤の組成物
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20080194019A1 (en) * 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
KR20070027747A (ko) * 2004-06-30 2007-03-09 콤비네이토릭스, 인코포레이티드 대사 질환의 치료 방법 및 시약
WO2006021008A2 (en) * 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
WO2006024489A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Methods and compositions for the treatment of cell proliferation
US20070105790A1 (en) * 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
US20080070867A1 (en) 2005-01-19 2008-03-20 Metabasis Therapeutics, Inc. 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases
EP1841415A2 (en) * 2005-01-20 2007-10-10 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
US20070015839A1 (en) 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
CN103172592B (zh) * 2006-01-05 2016-01-06 伊森舍丽斯有限公司 钾atp 通道开放剂的盐及其用途
CA2637027A1 (en) 2006-01-10 2007-07-19 Ruey J. Yu N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
JP5474356B2 (ja) * 2006-01-12 2014-04-16 デブジェン エヌブイ ＲＮＡｉを使用する害虫を制御する方法
US7659281B2 (en) 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
TWI440456B (zh) * 2007-01-16 2014-06-11 用於治療代謝性症候群之新穎化合物
DE102007052656B4 (de) * 2007-11-05 2010-03-25 Texas Instruments Deutschland Gmbh Digital-Verschlüsselungs-Hardware-Beschleuniger

Also Published As

Publication number Publication date
EP2702988A2 (en) 2014-03-05
JP2015007134A (ja) 2015-01-15
JP5697853B2 (ja) 2015-04-08
CA2666036A1 (en) 2009-11-16
DK2123267T3 (en) 2017-01-16
ES2608982T3 (es) 2017-04-17
MY162563A (en) 2017-06-30
ZA201008201B (en) 2012-08-29
JP6430774B2 (ja) 2018-11-28
CN106983759A (zh) 2017-07-28
EP2123267B1 (en) 2016-09-28
MX2010012549A (es) 2011-11-02
RU2010151609A (ru) 2012-06-27
TW201002311A (en) 2010-01-16
CA2666036C (en) 2017-09-12
JP2010013438A (ja) 2010-01-21
BRPI0903359B8 (pt) 2021-05-25
US8367645B2 (en) 2013-02-05
BRPI0903359B1 (pt) 2020-10-20
US20090286760A1 (en) 2009-11-19
IL209336A0 (en) 2011-01-31
KR20110063398A (ko) 2011-06-10
CL2009001215A1 (es) 2009-08-21
AU2009201946A1 (en) 2009-12-03
CN102098914A (zh) 2011-06-15
BRPI0903359A2 (pt) 2010-11-03
KR20160037245A (ko) 2016-04-05
WO2009140680A1 (en) 2009-11-19
RU2563833C2 (ru) 2015-09-20
AU2009201946B2 (en) 2015-01-15
IL209336B (en) 2018-07-31
KR101627877B1 (ko) 2016-06-07
EP2123267A1 (en) 2009-11-25
TWI496572B (zh) 2015-08-21
SA109300299B1 (ar) 2014-07-02
EP2702988A3 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
AR072454A1 (es) Composiciones que comprenden aspirina, metformina y clorhidrato de serotonina y metodos para el tratamiento de enfermedades hiperproliferativas
AR065837A1 (es) Composicion para el tratamiento del sindrome metabolico
JP2010013438A5 (ja) 過剰増殖性疾患を治療するための新規な組成物
AR095631A1 (es) Composición farmacéutica que comprende un activador ampk y un agente de serotonergico y métodos de uso
AR051405A1 (es) Compuestos de 2-carboxamido(3-amino)tiofeno
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
AR063097A1 (es) Pirazolopirimidinas[1,5-a] inhibidoras de quinasas dependientes de ciclina(cdk), composiciones farmaceuticas que las contienen y usos en el tratamiento de enfermedades proliferativas
AR079208A2 (es) Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP099608A (es) Preparacion solida que comprende alogliptina y pioglitazona
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2009000316A1 (es) Compuestos derivados de urea de benzomorfanos y sus sales, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de trastornos metabolicos.
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CR8163A (es) Composicion farmaceutica que contiene un inhibidor de histona desacetilasa
GT200500307A (es) Compuestos quimicos
PE20061389A1 (es) Formulacion farmaceutica que contiene biguanida y un derivado de tiazolidinadiona
ECSP088296A (es) Compuestos terapéuticos
JP2012520883A5 (es)
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
AR057162A1 (es) Compuestos de benzamida como inhibidores de la enzima histona desacetilasa (hdac)
UY29181A1 (es) Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones
CL2007003557A1 (es) Compuestos derivados de heterociclos de nitrogeno, inhibidores de la actividad sobre b-raf; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.

Legal Events

Date Code Title Description
FC Refusal